Chinese and Hong Kong equities closed higher on August 20 as a broader recovery across Asian markets lifted healthcare shares and helped heavily sold-off technology stocks rebound. The Shanghai Composite Index rose 0.24% to 3,903.7210, while the CSI 300 gained 0.09% to 4,592.750. Hong Kong’s Hang Seng Index advanced 0.80% to 25,698.49, and the Hang Seng China Enterprises Index added 0.90% to 8,547.84. Healthcare stocks led the advance after Moderna said its messenger RNA (mRNA) cancer vaccine, developed with Merck, reduced the risk of melanoma recurrence and metastasis in a late-stage trial. China’s CSI Vaccine & Biotechnology Index rose 9%, and Hong Kong’s Hang Seng Innovative Drug Index gained more than 4%. Technology stocks also recovered, supported by buyback and stock-acquisition announcements from companies including Foxconn Industrial Internet and CCCC Design & Consulting. Investors are watching U.S. interest rates and global bond yields, as higher funding costs could pressure AI-related capital expenditure, while progress toward commercializing Moderna and Merck’s vaccine may sustain interest in Chinese biopharmaceutical companies.